5-31 | An outbreak of yellow fever has been ravaging Angola since December 2015, raising fears that the disease will spread to other African countries or Asia. The limited stocks of vaccines constitute a particular challenge. Michel Van Herp, an epidemiologist with MSF, gave us an update on the situation. What are the characteristics of yellow fever? It is a disease caused by a virus, considered to be a haemorrhagic fever. The virus is transmitted by the Aedes mosquito.
5-26 | With simultaneous epidemics of meningitis and measles in Niger, teams from Médecins Sans Frontières/Doctors Without Borders (MSF) have been supporting the Ministry of Health in its efforts to bring them under control, while taking steps to prevent cholera spreading from neighbouring Nigeria.
MSF calls on G7 leaders to urgently address the critical gaps in global response to public health emergencies and unite to lower the price of live-saving medicines
5-26 | Two years since the first signs of the West Africa Ebola outbreak, the world today is little more prepared to respond to such an emergency than it was then, warns international humanitarian aid organisation Médecins Sans Frontières (MSF), while the lack of R&D into needed medicines and exorbitant medicine prices requires urgent and united action from the world leaders gathered in Japan. Global Health Systems: ‘Don’t build a hospital without an emergency room’ As the leaders of the G7 countries* gather in Ise-Shim
Access Campaign: Just 2% of people with the severest cases of drug-resistant TB currently have access to new, more effective treatments that could save their lives
3-21 | Two years after two new drugs to treat tuberculosis—the first in over 50 years—were conditionally approved for use, only 2% of the 150,000 people who need them have been able to access them, according to Médecins Sans Frontières (MSF).
MSF launches challenge to Pfizer’s patent on the pneumonia vaccine in India, to increase access to more affordable versions
3-11 | Médecins Sans Frontières/Doctors Without Borders (MSF) has filed a ‘patent opposition’ in India to prevent US pharmaceutical company Pfizer from getting a patent on the pneumococcal conjugate vaccine (PCV13), so more affordable versions can become available to developing countries and humanitarian organisations.